Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label Phase 2 trial assessing REC 3599

Next Previous
X
Search
Trial Profile

An open-label Phase 2 trial assessing REC 3599

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications GM2 gangliosidoses
  • Focus Therapeutic Use
  • Sponsors Recursion Pharmaceuticals

    • Most Recent Events

    • 03 Mar 2022 According to a Recursion Pharmaceuticals media release, company has decided to conduct a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest of patients before enrolling infants in a Phase 2 trial of REC-3599 in the ultra-rare indication infantile GM2 gangliosidosis. This decision will delay the GM2 Phase 2 trial start by approximately 2 years.
    • 10 Nov 2021 According to Recursion Pharmaceuticals media release, the company plans to initiate a Phase 2 study of REC-3599 in the first half of 2022.
    • 20 May 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top